TY - JOUR
T1 - Investigation of the Associations of Smoking With Hip Osteoarthritis
T2 - A Baseline Cross-Sectional and Four- to Five-Year Longitudinal Multicohort Study
AU - Salis, Zubeyir
N1 - Funding Information:
This study acknowledges the provision of data sets and/or research tools from two cohort studies: the Osteoarthritis Initiative (OAI) study and the Cohort Hip and Cohort Knee (CHECK) study. The OAI is a collaborative informatics system created by the National Institute of Mental Health and the National Institute of Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) to provide a worldwide resource to quicken the pace of biomarker identification, scientific investigation, and osteoarthritis drug development. The OAI is a public–private partnership comprising five contracts (N01‐AR‐2‐2258, N01‐AR‐2‐2259, N01‐AR‐2‐2260, N01‐AR‐2‐2261, and N01‐AR‐2‐2262) funded by the NIH, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the NIH. This article was prepared using OAI public‐use data sets and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. The OAI data repository is housed within the National Institute of Mental Health Data Archive. The Dutch Arthritis Foundation funds the CHECK study. Involved are Erasmus Medical Center Rotterdam, Kennemer Gasthuis Haarlem, Leiden University Medical Center, Maastricht University Medical Center, Martini Hospital Groningen/Allied Health Care Center for Rheumatology and Rehabilitation Groningen, Medical Spectrum Twente Enschede/Ziekenhuisgroep Twente Almelo, Reade Center for Rehabilitation and Rheumatology, Sint Maartens‐kliniek Nijmegen, University Medical Center Utrecht, and Wilhelmina Hospital Assen.
Publisher Copyright:
© 2024 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
PY - 2024/3
Y1 - 2024/3
N2 - Objective: This study aimed to investigate the effect of smoking on the prevalence, incidence, and progression of hip osteoarthritis (OA). We used data from the Osteoarthritis Initiative (OAI) and the Cohort Hip and Cohort Knee (CHECK) studies. Methods: We analyzed 9,386 hips from 4,716 participants (OAI cohort) and 1,954 hips from 977 participants (CHECK cohort). The primary exposure was smoking status at baseline, categorized as current, former, or never smoker. Outcomes of radiographic hip OA (RHOA) and symptomatic hip OA were evaluated both cross-sectionally at baseline and longitudinally over a 4- to 5-year follow-up, with adjustments for major covariates. Results: No significant differences were observed between current or former smokers and never smokers for any of the outcomes examined, either at baseline or at the 4- to 5-year follow-up. In the cross-sectional analysis, the odds ratios with 95% confidence intervals for the prevalence of RHOA for current and former smokers were 1.29 (0.68–2.46) and 0.99 (0.70–1.40) in the OAI cohort and 1.38 (0.78–2.44) and 0.85 (0.54–1.32) in the CHECK cohort, respectively. In the longitudinal analysis, odds ratio with 95% confidence intervals for the incidence of RHOA were 1.03 (0.23–4.50) and 0.92 (0.46–1.85) in the OAI cohort and 0.61 (0.34–1.11) and 1.00 (0.69–1.44) in the CHECK cohort, respectively. Conclusion: Our study found no clear association between smoking and the prevalence, incidence, or progression of RHOA or symptomatic hip OA, either at baseline or over a 4- to 5-year period.
AB - Objective: This study aimed to investigate the effect of smoking on the prevalence, incidence, and progression of hip osteoarthritis (OA). We used data from the Osteoarthritis Initiative (OAI) and the Cohort Hip and Cohort Knee (CHECK) studies. Methods: We analyzed 9,386 hips from 4,716 participants (OAI cohort) and 1,954 hips from 977 participants (CHECK cohort). The primary exposure was smoking status at baseline, categorized as current, former, or never smoker. Outcomes of radiographic hip OA (RHOA) and symptomatic hip OA were evaluated both cross-sectionally at baseline and longitudinally over a 4- to 5-year follow-up, with adjustments for major covariates. Results: No significant differences were observed between current or former smokers and never smokers for any of the outcomes examined, either at baseline or at the 4- to 5-year follow-up. In the cross-sectional analysis, the odds ratios with 95% confidence intervals for the prevalence of RHOA for current and former smokers were 1.29 (0.68–2.46) and 0.99 (0.70–1.40) in the OAI cohort and 1.38 (0.78–2.44) and 0.85 (0.54–1.32) in the CHECK cohort, respectively. In the longitudinal analysis, odds ratio with 95% confidence intervals for the incidence of RHOA were 1.03 (0.23–4.50) and 0.92 (0.46–1.85) in the OAI cohort and 0.61 (0.34–1.11) and 1.00 (0.69–1.44) in the CHECK cohort, respectively. Conclusion: Our study found no clear association between smoking and the prevalence, incidence, or progression of RHOA or symptomatic hip OA, either at baseline or over a 4- to 5-year period.
UR - http://www.scopus.com/inward/record.url?scp=85181499411&partnerID=8YFLogxK
U2 - 10.1002/acr2.11644
DO - 10.1002/acr2.11644
M3 - Article
C2 - 38174808
AN - SCOPUS:85181499411
SN - 2578-5745
VL - 6
SP - 155
EP - 166
JO - ACR Open Rheumatology
JF - ACR Open Rheumatology
IS - 3
ER -